TherapeuticsMD (TXMD) Tops Q3 EPS by 2c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
TherapeuticsMD® Announces Third Quarter 2020 Financial Results
November 9, 2020 6:55 AM ESTSignificant growth in net revenue, net revenue per unit and prescriptions across product portfolio
Total net revenue increased 80% to $19.3 million compared to 2Q20
ANNOVERA® net revenue increased 250% for 3Q20 compared to 2Q20
Menopausal products achieved double digit growth in new and total prescriptions for 3Q20 compared to 2Q20
Reduced 3Q20 cash burn by $22 million compared to 2Q20
Process to divest vitaCare Prescription Services underway that could generate non-dilutive proceeds
Sixth Street reduces minimum cash requirement from... More
